DOCSLIB.ORG

A Severe Form of Abetalipoproteinemia Caused by New Splicing Mutations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

A severe form of abetalipoproteinemia caused by new splicing mutations of microsomal triglyceride transfer protein Véronique Pons, Corinne Rolland, Michel Nauze, Marie Danjoux, Gérald Gaibelet, Anne H. Durandy, Agnes Sassolas, Emile Lévy, François Tercé, Xavier Collet, et al. To cite this version: Véronique Pons, Corinne Rolland, Michel Nauze, Marie Danjoux, Gérald Gaibelet, et al.. A severe form of abetalipoproteinemia caused by new splicing mutations of microsomal triglyceride transfer protein. Human Mutation, Wiley, 2011, 32 (7), pp.751. 10.1002/humu.21494. hal-00651635 HAL Id: hal-00651635 https://hal.archives-ouvertes.fr/hal-00651635 Submitted on 14 Dec 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Human Mutation A severe form of abetalipoproteinemia caused by new splicing mutations of microsomal triglyceride transfer protein For Peer Review Journal: Human Mutation Manuscript ID: humu-2010-0522.R1 Wiley - Manuscript type: Research Article Date Submitted by the 07-Feb-2011 Author: Complete List of Authors: Pons, Véronique; INSERM, U1048; Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires Rolland, Corinne; INSERM, U1043; Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan (CPTP) Nauze, Michel; INSERM, U1048; Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires Danjoux, Marie; CHU Toulouse, Hôpital Purpan, Département d’Anatomopathologie Gaibelet, Gérald; INSERM, U1048; Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires Durandy, Anne; INSERM U768, Université Paris V-René Descartes, Hôpital Necker-Enfants Malades Sassolas, Agnes; UF Dyslipidémies, CBPE, Hospices Civils de Lyon and Lyon University, INSERM U1060, CarMeN Laboratory, Univ Lyon-1 Lévy, Emile; Départements de Nutrition et de Biochimie, Hôpital Sainte-Justine et Université de Montréal Tercé, François; INSERM, U1048; Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires Collet, Xavier; INSERM, U1048; Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires MAS, Emmanuel; INSERM, U1043; Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan (CPTP); CHU Toulouse, Hôpital des Enfants, Unité de Gastroentérologie, Hépatologie et Nutrition, Département de Pédiatrie abetalipoproteinemia, MTTP, triglyceride transfer, endoplasmic Key Words: reticulum, intestinal HDL John Wiley & Sons, Inc. Page 2 of 78 Human Mutation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 For Peer Review 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 John Wiley & Sons, Inc. Human Mutation Page 3 of 78 New splicing mutations of MT TP 1 Formatted: Font: Italic 1 2 A severe form of abetalipoproteinemia caused by new splicing mutations of microsomal 3 4 triglyceride transfer protein 5 1, 6 1,2 3,4 1,2 5 Deleted : Véronique Pons , Corinne Rolland , Michel Nauze , Marie Danjoux , Gérald Gaibelet 2…3 Deleted : ... [1] 7 1,2 6 7 8 1,2 1,2 8 , Anne Durandy , Agnès Sassolas , Emile Lévy , François Tercé , Xavier Collet * Deleted : 4 9 and Emmanuel Mas 3,4,9* Deleted : 4 5 10 Deleted : 11 Deleted : 5 1 12 INSERM, U1048 , Toulouse, F-31 000 , France; Deleted : 6 13 6 2Université Toulouse III, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, Deleted : 14 7…1, Deleted : ... [2] 15 F-31300 France; 2…7 Deleted : ... [3] 16 3 INSERM, U1043, Toulouse, F-31300 France; Deleted : 8 17 8 18 4Université de Toulouse , UPS, Centre de Physiopathologie de Toulouse Purpan (CPTP) , Deleted : 19 Formatted: Font: (Default) Times Toulouse, F-31300 , France; New Roman, Complex Script Font: 20 For Peer Review Times New Roman, French France 5CHU Toulouse, Hôpital Purpan, Département d’Anatomopathologie, Toulouse, F-31300 21 Deleted : U563… ... [4] 22 France; Deleted : 3 23 Formatted 6INSERM U768, Université Paris V-René Descartes, Hôpital Necker-Enfants Malades, 75015 ... [5] 24 Deleted : 25 Paris (France); Formatted 26 ... [6] 7 27 UF Dyslipidémies, CBPE, Hospices Civils de Lyon and Lyon University, INSERM U1060, Deleted : France 28 Formatted ... [7] CarMeN Laboratory, Univ Lyon-1 F-69621, Villeurbanne (France); 3 29 Deleted : 8 30 Départements de Nutrition et de Biochimie, Hôpital Sainte-Justine et Université de Montréal, Formatted: Superscript 31 Montréal, Québec (Canada); Deleted : III Paul-Sabatier, Deleted : 4 32 9 33 CHU Toulouse, Hôpital des Enfants, Unité de Gastroentérologie, Hépatologie et Nutrition, Deleted : 3 34 Département de Pédiatrie, Toulouse, F-31300 , France. Deleted : Hôpital Purpan, 35 4 * These authors equally contributed to the work Deleted : 36 5… Deleted : , ... [8] 37 Deleted : Université Paris Descartes, 38 Faculté de Médecine Paris V-René 39 Corresponding author: Descartes, 40 Emmanuel Mas, MD Deleted : 5 41 Deleted : 6 Hôpital des Enfants - Unité de Gastroentérologie, Hépatologie et Nutrition – 330 avenue de 42 Formatted ... [9] 43 Grande-Bretagne – TSA 70034 – 31059 Toulouse cedex 9 (France) Deleted : Laboratoire des 44 Dyslipidémies, Centre de Biologie Est, Tel. (33) 5 34 55 84 45 Lyon 45 Deleted : 6 46 Fax. (33) 5 34 55 85 67 Deleted : 7 47 E-mail: [email protected] 7 48 Deleted : 8… 49 Deleted : Hôpital des Enfants, ... [10] 50 Deleted : 9¶ 51 52 53 54 55 56 57 58 59 60 John Wiley & Sons, Inc. Page 4 of 78 Human Mutation New splicing mutations of MT TP 2 Formatted: Font: Italic 1 2 ABSTRACT 3 4 Abetalipoproteinemia is a rare autosomal recessive disease characterized by low lipid levels 5 and by the absence of apoB-containing lipoproteins. It is the consequence of microsomal 6 7 triglyceride transfer protein (MT TP) deficiency. Deleted : ed 8 We report 2 patients with new MTTP mutations. We studied their functional consequences on 9 Deleted : MTP MTTP 10 the triglyceride transfer function using duodenal biopsies. We transfected mutants in Formatted: Font: Italic 11 HepG2 and HeLa cells to investigate their association with protein disulfide isomerase ( PDI ) Deleted : MTP 12 Formatted: Font: Italic and their localization at the endoplasmic reticulum. 13 Formatted: Font: Italic 14 These children have a severe abetalipoproteinemia. Both of them had also a mild 15 hypogammaglobulinemia. They are compound heterozygotes with c.619G>T and c.1237- 16 Deleted : mttp 17 28A>G mutations within MTTP gene. mRNA analysis revealed abnormal splicing with 18 Formatted: Font: Italic deletion of exon 6 and 10, respectively. Deletion of exon 6 (∆6-MTTP ) introduced a frame 19 Formatted: Font: Italic 20 shift in the reading frame andFor a premature Peerstop codon at position Review 234. Despite ∆6-MTTP and Deleted : MTP 21 Formatted: Font: Italic ∆ 22 10-MTTP mutants were not capable of binding PDI, both MTTP mutant proteins normally Deleted : MTP 23 localize at the endoplasmic reticulum. However, these two mutations induce a loss of MTTP Formatted: Font: Italic 24 Deleted : MTP triglyceride transfer activity. 25 Deleted : MTP 26 These two mutations lead to abnormal truncated MTTP proteins, incapable of binding PDI Deleted : MTP 27 and responsible for the loss of function of MTTP , thereby explaining the severe Deleted : MTP 28 Deleted : MTP 29 abetalipoproteinemia phenotype of these children. 30 31 Deleted : MTP 32 Keywords: abetalipoproteinemia, MTTP , triglyceride transfer, intestinal HDL, endoplasmic 33 Formatted: Font: Italic 34 reticulum 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 John Wiley & Sons, Inc. Human Mutation Page 5 of 78 New splicing mutations of MT TP 3 Formatted: Font: Italic 1 2 INTRODUCTION 3 4 Abetalipoproteinemia (ABL, OMIM 200100) is a rare autosomal recessive disease 5 Deleted : MTP 6 caused by the deficiency of the microsomal triglyceride transfer protein (MTTP, OMIM 7 8 157147 ). ABL is characterized by the absence of apolipoprotein B (apoB)-containing 9 Deleted : MTP 10 lipoproteins from plasma. MTTP is a 97 kDa protein, containing 894 amino acids, that forms 11 Deleted : MTP 12 a heterodimer with the 55 kDa protein disulfide isomerase (PDI). MTTP is mainly found in 13 14 the endoplasmic reticulum (ER) of hepatocytes and enterocytes (Wetterau, et al., 1992). 15 Deleted : MTP 16 MTTP is required for the transfer of neutral lipids to nascent apoB-lipoproteins, resulting in 17 18 the secretion of very low-density lipoproteins (VLDL) in the liver or chylomicrons (CM) in 19 Deleted : MTP 20 the intestine. When MTTP is Fordeficient, nascent Peer apoB is degraded Review by the proteasome (Benoist Formatted: Font: Italic 21 Deleted : (Zhou, et al., 1998) 22 and Grand-Perret, 1997) . It differs from familial hypobetalipoproteinemia, displaying 23 24 dysfunctional apoB and leading to the absence of apoB-lipoproteins in the plasma. Familial 25 26 hypobetalipoproteinemia is a co-dominant disorder and even if heterozygotes can be 27 28 asymptomatic, they had low levels of total cholesterol (TC), low density lipoprotein (LDL)- 29 30 cholesterol and apoB (OMIM 107730). 31 Deleted : MTP 32 ABL was characterized as the consequence of MTTP absence or dysfunction in 1992 33 Deleted : mttp 34 by Wettereau et al. (Wetterau, et al., 1992). The genetic defects in MTTP gene, located on Formatted: Font: Italic 35 36 chromosome 4q22-24, were confirmed one year later (Sharp, et al., 1993; Shoulders, et al., 37 38 1993). ABL is a very uncommon disease, which highlights the crucial role of this protein. 39 Deleted : MTP Indeed, the mttp -deficient mice died at embryonic day 10.5 with abnormal neurological 40 41 development (exencephalia) (Raabe, et al., 1998).
Recommended publications
  • Studies on the Absorptive Defect for Triglyceride in Abetalipoproteinemia * P

    Studies on the Absorptive Defect for Triglyceride in Abetalipoproteinemia * P

    Jownal of Clinical Investigation Vol. 46, No. 1, 1967 Studies on the Absorptive Defect for Triglyceride in Abetalipoproteinemia * P. 0. WAYS,t C. M. PARMENTIER, H. J. KAYDEN,4 J. W. JONES,§ D. R. SAUNDERS,|| AND C. E. RUBIN 1J (From the Department of Medicine, University of Washington School of Medicine, Seattle, Wash., and the Department of Medicine, New York University School of Medicine, New York, N. Y.) Summary. The nature of the gastrointestinal absorptive defect for triglycer- ide in three subjects with abetalipoproteinemia has been investigated by studying peroral biopsies of the gastrointestinal mucosa. The following con- clusions were reached. 1) In confirmation of other studies, the abnormal vacuoles within the du- odenal absorptive cells of these individuals were lipophilic. 2) On chemical analysis there was significantly more mucosal lipid than found in normal fasting specimens, and almost the entire increase was due to triglyceride. 3) This excess mucosal lipid was reduced by a low fat diet, but even after 34 days on such a diet there was still an excess of lipophilic material near the villus tip and increased quantities of total lipid and triglyceride when com- pared with material from normal subjects similarly treated. 4) Although there are demonstrable qualitative changes in mucosal and plasma lipids after an acute fat load, they are not quantitatively as great as in normal individuals. Fat balance studies and the qualitative changes in plasma and tissue lipids that do occur after more extended periods on different types of dietary fat do indicate that a considerable percentage of the dietary fat is assimilated.
  • Case Report: Eruptive Xanthoma in a 14-Year-Old Boy Ryan M

    Case Report: Eruptive Xanthoma in a 14-Year-Old Boy Ryan M

    Case Report: Eruptive Xanthoma in a 14-year-old boy Ryan M. Proctor, DO; Warren A. Peterson, DO; Michael W. Peterson, DO: Michael R. Proctor, DO; J. Ryan Jackson, DO; Andrew C. Duncanson OMS4; Allen E. Stout, DC. Dr. R. Proctor, Dr. W. Peterson, Dr. M. Peterson are from Aspen Dermatology Residency, Spanish Fork, UT; Dr. M. Proctor is from Arizona Desert Dermatology, Kingman, AZ; Dr. Jackson is from Sampson Regional Medical Center, Clinton, NC; OMS4 Duncanson is from Des Moines University, Des Moines, IA; DC Stout is from Stout Wellness Center, Fort Mohave, AZ. INTRODUCTION CLINICAL PHOTOS DISCUSSION Xanthomas are benign collections of lipid deposits that manifest as yellow to Eruptive xanthomas (EX) are often an indicator of severe red firm papules, nodules, or plaques. This yellow/red coloration is due to the hypertriglyceridemia and can indicate undiagnosed or Figure 1 Figure 2 carotene in lipids. Xanthomas are composed of lipid filled macrophages decompensated diabetes mellitus (DM).1 The triglyceride levels in known as “foam cells”. Xanthomas can be due to genetic disorders of lipid these patients can be >3000-4000 mg/dl (normal <150 mg/dl).2 metabolism, such as autosomal dominant hypocholesteremia or familial lipoprotein lipase(LPL) deficiency.1,2 They can also be caused by severe It is important to quickly diagnose and manage these patients due hypertriglyceridemia and have been associated with undiagnosed diabetic to the possible sequela of diabetes mellitus and hyperlipidemia. dyslipidemia, hypothyroidism, cholestasis, nephrotic
  • Hypocholesterolemia in Patients with Polycythemia Vera

    Hypocholesterolemia in Patients with Polycythemia Vera

    J Clin Exp Hematopathol Vol. 52, No. 2, Oct 2012 Original Article Hypocholesterolemia in Patients with Polycythemia Vera Hiroshi Fujita,1) Tamae Hamaki,2) Naoko Handa,2) Akira Ohwada,2) Junji Tomiyama,2) and Shigeko Nishimura1) Polycythemia vera (PV) is characterized by low serum total cholesterol despite its association with vascular events such as myocardialand cerebralinfarction. Serum cholesterollevelhasnot been used as a diagnostic criterion for PV since the 2008 revision of the WHO classification. Therefore, we revisited the relationship between serum lipid profile, including total cholesterol level, and erythrocytosis. The medical records of 34 erythrocytosis patients (hemoglobin : men, > 18.5 g/dL ; women, > 16.5 g/dL) collected between August 2005 and December 2011 were reviewed for age, gender, and lipid profiles. The diagnoses of PV and non-PV erythrocytosis were confirmed and the in vitro efflux of cholesterol into plasma in whole blood examined. The serum levels of total cholesterol, low-density-lipoprotein cholesterol (LDL-Ch), and apolipoproteins A1 and B were lower in PV than in non-PV patients. The in vitro release of cholesterol into the plasma was greater in PV patients than in non-PV and non-polycythemic subjects. Serum total cholesterol, LDL-Ch, and apolipoproteins A1 and B levels are lower in patients with PV than in those with non-PV erythrocytosis. The hypocholesterolemia associated with PV may be attributable to the sequestration of circulating cholesterol into the increased number of erythrocytes. 〔J Clin Exp Hematopathol 52(2) : 85-89, 2012〕 Keywords: polycythemia vera, JAK2 V617F mutation, hypocholesterolemia rocytosis without the JAK2 V167F mutation.5 Although the INTRODUCTION serum cholesterol level in PV patients has been studied Polycythemia vera (PV) is classified as a myeloprolifera- previously,6 it has not been used as a diagnostic criterion for tive neoplasm and usually occurs in people aged 60-79 years.
  • Bovine Milk Lipoprotein Lipase Transfers Tocopherol to Human Fibroblasts During Triglyceride Hydrolysis in Vitro Maret G

    Bovine Milk Lipoprotein Lipase Transfers Tocopherol to Human Fibroblasts During Triglyceride Hydrolysis in Vitro Maret G

    Bovine Milk Lipoprotein Lipase Transfers Tocopherol to Human Fibroblasts during Triglyceride Hydrolysis In Vitro Maret G. Traber, Thomas Olivecrona, and Herbert J. Kayden Department ofMedicine, New York University School ofMedicine, New York 10016; University of Umea, Umea, Sweden Abstract vitamin E, have minimal or absent neurological abnormalities, but those who have not been supplemented have a progressive Lipoprotein lipase appears to function as the mechanism by which dietary vitamin E (tocopherol) is transferred from chy- degeneration of the peripheral nervous system resulting in ataxia and characteristic pathologic changes in the central lomicrons to tissues. In patients with lipoprotein lipase defi- nervous system (5). These neuropathologic changes have been more than 85% of both the and ciency, circulating triglyceride observed in patients with cholestatic liver disease in whom the tocopherol is contained in the chylomicron fraction. The studies in low to absent levels of bile salts in the intestine results in an presented here show that the vitro addition of bovine milk inability to absorb vitamin E (3). Oral supplementation with to in the of lipoprotein lipase (lipase) chylomicrons presence pharmacologic amounts of the vitamin (6), or or fibroblasts bovine albumin pagenteral human erythrocytes (and serum administration of the vitamin (when there is a complete resulted in the hydrolysis of triglyceride and the [BSAJ) the absence of intestinal bile) (7) results in the prevention of transfer of both acids and to the in the fatty tocopherol cells; further of the nervous system. The studies in absence of no in cellular was deterioration lipase, increase tocopherol these two groups ofpatients have demonstrated the importance The incubation was to include detectable.
  • Apoa5genetic Variants Are Markers for Classic Hyperlipoproteinemia

    Apoa5genetic Variants Are Markers for Classic Hyperlipoproteinemia

    CLINICAL RESEARCH CLINICAL RESEARCH www.nature.com/clinicalpractice/cardio APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia 1 1 1 2 2 1 1 Jian Wang , Matthew R Ban , Brooke A Kennedy , Sonia Anand , Salim Yusuf , Murray W Huff , Rebecca L Pollex and Robert A Hegele1* SUMMARY INTRODUCTION Hypertriglyceridemia is a common biochemical Background Several known candidate gene variants are useful markers for diagnosing hyperlipoproteinemia. In an attempt to identify phenotype that is observed in up to 5% of adults. other useful variants, we evaluated the association of two common A plasma triglyceride concentration above APOA5 single-nucleotide polymorphisms across the range of classic 1.7 mmol/l is a defining component of the meta­ 1 hyperlipoproteinemia phenotypes. bolic syndrome and is associated with several comorbidities, including increased risk of cardio­ Methods We assessed plasma lipoprotein profiles and APOA5 S19W and vascular disease2 and pancreatitis.3,4 Factors, –1131T>C genotypes in 678 adults from a single tertiary referral lipid such as an imbalance between caloric intake and clinic and in 373 normolipidemic controls matched for age and sex, all of expenditure, excessive alcohol intake, diabetes, European ancestry. and use of certain medications, are associated Results We observed significant stepwise relationships between APOA5 with hypertriglyceridemia; however, genetic minor allele carrier frequencies and plasma triglyceride quartiles. The factors are also important.5,6 odds ratios for hyperlipoproteinemia types 2B, 3, 4 and 5 in APOA5 S19W Complex traits, such as plasma triglyceride carriers were 3.11 (95% CI 1.63−5.95), 4.76 (2.25−10.1), 2.89 (1.17−7.18) levels, usually do not follow Mendelian patterns of and 6.16 (3.66−10.3), respectively.
  • The Nuclear Envelope in Lipid Metabolism and Pathogenesis of NAFLD

    The Nuclear Envelope in Lipid Metabolism and Pathogenesis of NAFLD

    biology Review The Nuclear Envelope in Lipid Metabolism and Pathogenesis of NAFLD Cecilia Östlund 1,2, Antonio Hernandez-Ono 1 and Ji-Yeon Shin 1,* 1 Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA; [email protected] (C.Ö.); [email protected] (A.H.-O.) 2 Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA * Correspondence: [email protected]; Tel.: +1-212-305-4088 Received: 9 September 2020; Accepted: 12 October 2020; Published: 15 October 2020 Simple Summary: The liver is a major organ regulating lipid metabolism and a proper liver function is essential to health. Nonalcoholic fatty liver disease (NAFLD) is a condition with abnormal fat accumulation in the liver without heavy alcohol use. NAFLD is becoming one of the most common liver diseases with the increase in obesity in many parts of the world. There is no approved cure for the disease and a better understanding of disease mechanism is needed for effective prevention and treatment. The nuclear envelope, a membranous structure that surrounds the cell nucleus, is connected to the endoplasmic reticulum where the vast majority of cellular lipids are synthesized. Growing evidence indicates that components in the nuclear envelope are involved in cellular lipid metabolism. We review published studies with various cell and animal models, indicating the essential roles of nuclear envelope proteins in lipid metabolism. We also discuss how defects in these proteins affect cellular lipid metabolism and possibly contribute to the pathogenesis of NAFLD.
  • Commonly Used Lipidcentric ICD-10 (ICD-9) Codes

    Commonly Used Lipidcentric ICD-10 (ICD-9) Codes

    Commonly Used Lipidcentric ICD-10 (ICD-9) Codes *This is not an all inclusive list of ICD-10 codes R.LaForge 11/2015 E78.0 (272.0) Pure hypercholesterolemia E78.3 (272.3) Hyperchylomicronemia (Group A) (Group D) Familial hypercholesterolemia Grütz syndrome Fredrickson Type IIa Chylomicronemia (fasting) (with hyperlipoproteinemia hyperprebetalipoproteinemia) Hyperbetalipoproteinemia Fredrickson type I or V Hyperlipidemia, Group A hyperlipoproteinemia Low-density-lipoid-type [LDL] Lipemia hyperlipoproteinemia Mixed hyperglyceridemia E78.4 (272.4) Other hyperlipidemia E78.1 (272.1) Pure hyperglyceridemia Type 1 Diabetes Mellitus (DM) with (Group B) hyperlipidemia Elevated fasting triglycerides Type 1 DM w diabetic hyperlipidemia Endogenous hyperglyceridemia Familial hyperalphalipoproteinemia Fredrickson Type IV Hyperalphalipoproteinemia, familial hyperlipoproteinemia Hyperlipidemia due to type 1 DM Hyperlipidemia, Group B Hyperprebetalipoproteinemia Hypertriglyceridemia, essential E78.5 (272.5) Hyperlipidemia, unspecified Very-low-density-lipoid-type [VLDL] Complex dyslipidemia hyperlipoproteinemia Elevated fasting lipid profile Elevated lipid profile fasting Hyperlipidemia E78.2 (272.2) Mixed hyperlipidemia (Group C) Hyperlipidemia (high blood fats) Broad- or floating-betalipoproteinemia Hyperlipidemia due to steroid Combined hyperlipidemia NOS Hyperlipidemia due to type 2 diabetes Elevated cholesterol with elevated mellitus triglycerides NEC Fredrickson Type IIb or III hyperlipoproteinemia with E78.6 (272.6)
  • The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia: a Review

    The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia: a Review

    Review Article ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2020.26.004382 The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia: A Review Alaa Abousetta, Ibrahim Abousetta, Theresa Dobler, Lia Ebrahimi, Vassillis Frangoullis, Stephanos Christodoulides and Ioannis Patrikios* School of Medicine, European University Cyprus, Cyprus *Corresponding author: Ioannis Patrikios, School of Medicine, European University Cyprus, Cyprus ARTICLE INFO Abstract Received: March 06, 2020 Hypertriglyceridemia is a common problem in adults in the developed world. It is associated with increased levels of triglycerides within the blood, which subsequently Published: March 17, 2020 promote the development of other diseases such as cardiovascular disease and pancreatitis. Triglycerides are mostly consumed through the diet and act as a source of energy in between meals. However, the levels of triglycerides increase proportionally Citation: Alaa A, Ibrahim A, Theresa D, Lia with the number of calories consumed. This only leads to a problem if the total daily E, Ioannis P, et al., The Effect of Omega-3 energy expenditure is exceeded. Additionally, the type of macronutrients taken in Fatty Acids on Hypertriglyceridemia: A Re- view. Biomed J Sci & Tech Res 26(4)-2020. for instance, high carbohydrate intake has been associated with an increased plasma BJSTR. MS.ID.004382. triglyceridethrough the level.diet has If thea direct levels influence of the triglycerideson having an inincreased the blood level rise of abovetriglycerides, 150 mg/ as Abbreviations: FHTG: Familial hypertri- dL, it is considered as hypertriglyceridemia. Increasing numbers of triglycerides can glyceridemia; FCH: Familial Combined Hy- have multiple underlying causes, which can be divided into primary and secondary perlipidemia, systemic lupus erythemato- causes.
  • Fat Accumulation in Enterocytes: a Key to the Diagnosis of Abetalipoproteinemia Or Homozygous Hypobetalipoproteinemia

    Fat Accumulation in Enterocytes: a Key to the Diagnosis of Abetalipoproteinemia Or Homozygous Hypobetalipoproteinemia

    Cases and Techniques Library (CTL) E223 Fat accumulation in enterocytes: a key to the diagnosis of abetalipoproteinemia or homozygous hypobetalipoproteinemia Fig. 3 Microscopic image showing vacuo- lization, especially on the top of the villi. Vacuolization causes a paler aspect because of fat dissolving during the process of embed- ding the tissue in par- affin wax (“empty” vacuoles instead of fat accumulation). Fig. 4 Negative peri- Fig. 1 A 20-year-old woman was referred by odic acid-Schiff staining her ophthalmologist to investigate the reason shows no microorgan- for her hypovitaminosis A and secondary night isms nor accumulation blindness. A macroscopic image taken during of glycogen, supporting gastroscopy shows a pale duodenal mucosa. the assumption that the vacuolization is due to lipid accumulation. level of detection). Her level of 25-hydroxy These findings suggested a diagnosis of Fig. 2 Videocapsule image illustrating the vitamin D appeared to be normal, but at either abetalipoproteinemia or homo- pale yet pronounced aspect of the villi. the time of her first admission, vitamin D zygous hypolipobetaproteinemia, disor- substitution had already been started. A ders that are caused by mutations in both This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. slightly raised alanine aminotransferase alleles of the microsomal triglycerides A 20-year-old woman was referred by her was also detected (33U/L). transfer protein (MTP) or in the APO-B ophthalmologist to investigate the reason Further work-up excluded cystic fibrosis, gene, respectively [1–2] This results in for her hypovitaminosis A and secondary exocrine pancreas insufficiency, and celiac the failure of APO B-100 synthesis in the night blindness.
  • Other Types of Primary Hyperlipoproteinemia

    Other Types of Primary Hyperlipoproteinemia

    82 Journal of Atherosclerosis and Thrombosis Vol.21, No.2 Committee Report 10 Other Types of Primary Hyperlipoproteinemia (Hyperlipidemia) Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan ― 2012 Version Tamio Teramoto, Jun Sasaki, Shun Ishibashi, Sadatoshi Birou, Hiroyuki Daida, Seitaro Dohi, Genshi Egusa, Takafumi Hiro, Kazuhiko Hirobe, Mami Iida, Shinji Kihara, Makoto Kinoshita, Chizuko Maruyama, Takao Ohta, Tomonori Okamura, Shizuya Yamashita, Masayuki Yokode and Koutaro Yokote Committee for Epidemiology and Clinical Management of Atherosclerosis 1. Primary Hyperlipoproteinemias (Hyperlipidemias) enhanced hepatic apolipoprotein (apo) B-100 synthe- Other Than Familial Hypercholesterolemia sis, decreased LPL activity, increased very-low-density There are various types of primary hyperlipopro- lipoprotein (VLDL) secretion from the liver and the teinemias (hyperlipidemias) other than familial hyper- accumulation of visceral fat as factors for the develop- cholesterolemia (FH). These types are clinically ment of symptoms and has been reported to be related important and classified according to their associated to abnormalities of the LPL and APOC-Ⅱ genes or pathophysiology and genetic abnormalities (Table 1)1). APOA-Ⅰ/C-Ⅲ/A-Ⅳ gene cluster. However, none of Familial lipoprotein lipase (LPL) deficiency manifests these findings have been proven to be definitive. It has as severe hyperchylomicronemia and may present with also been suggested that FCHL is caused by a poly- eruptive cutaneous xanthomas or acute pancreatitis, genic background that tends to induce hyperlipopro- although it does not necessarily accompany atheroscle- teinemia due to environmental factors, such as over- rotic cardiovascular disease (CVD). On the other nutrition and a low level of physical activity.
  • Severe Hypertriglyceridemia in a Patient Heterozygous for a Lipoprotein Lipase Gene Allele with Two Novel Missense Variants

    Severe Hypertriglyceridemia in a Patient Heterozygous for a Lipoprotein Lipase Gene Allele with Two Novel Missense Variants

    European Journal of Human Genetics (2015) 23, 1259–1261 & 2015 Macmillan Publishers Limited All rights reserved 1018-4813/15 www.nature.com/ejhg SHORT REPORT Severe hypertriglyceridemia in a patient heterozygous for a lipoprotein lipase gene allele with two novel missense variants Ursula Kassner*,1, Bastian Salewsky2,3, Marion Wühle-Demuth1, Istvan Andras Szijarto1, Thomas Grenkowitz1, Priska Binner4, Winfried März4,5,6, Elisabeth Steinhagen-Thiessen1,2 and Ilja Demuth*,2,3 Rare monogenic hyperchylomicronemia is caused by loss-of-function mutations in genes involved in the catabolism of triglyceride-rich lipoproteins, including the lipoprotein lipase gene, LPL. Clinical hallmarks of this condition are eruptive xanthomas, recurrent pancreatitis and abdominal pain. Patients with LPL deficiency and severe or recurrent pancreatitis are eligible for the first gene therapy treatment approved by the European Union. Therefore the precise molecular diagnosis of familial hyperchylomicronemia may affect treatment decisions. We present a 57-year-old male patient with excessive hypertriglyceridemia despite intensive lipid-lowering therapy. Abdominal sonography showed signs of chronic pancreatitis. Direct DNA sequencing and cloning revealed two novel missense variants, c.1302A4T and c.1306G4A, in exon 8 of the LPL gene coexisting on the same allele. The variants result in the amino-acid exchanges p.(Lys434Asn) and p.(Gly436Arg). They are located in the carboxy-terminal domain of lipoprotein lipase that interacts with the glycosylphosphatidylinositol- anchored HDL-binding protein (GPIHBP1) and are likely of functional relevance. No further relevant mutations were found by direct sequencing of the genes for APOA5, APOC2, LMF1 and GPIHBP1. We conclude that heterozygosity for damaging mutations of LPL may be sufficient to produce severe hypertriglyceridemia and that chylomicronemia may be transmitted in a dominant manner, at least in some families.
  • Evaluation and Treatment of Hypertriglyceridemia: an Endocrine Society Clinical Practice Guideline

    Evaluation and Treatment of Hypertriglyceridemia: an Endocrine Society Clinical Practice Guideline

    SPECIAL FEATURE Clinical Practice Guideline Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline Lars Berglund, John D. Brunzell, Anne C. Goldberg, Ira J. Goldberg, Frank Sacks, Mohammad Hassan Murad, and Anton F. H. Stalenhoef University of California, Davis (L.B.), Sacramento, California 95817; University of Washington (J.D.B.), Seattle, Washington 98195; Washington University School of Medicine (A.C.G.), St. Louis, Missouri 63110; Columbia University (I.J.G.), New York, New York 10027; Harvard School of Public Health (F.S.), Boston, Massachusetts 02115; Mayo Clinic (M.H.M.), Rochester, Minnesota 55905; and Radboud University Nijmegen Medical Centre (A.F.H.S.), 6525 GA Nijmegen, The Netherlands Objective: The aim was to develop clinical practice guidelines on hypertriglyceridemia. Participants: The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration. Consensus Process: Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequen- tially by The Endocrine Society’s CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. Conclusions: The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150–999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hyper- triglyceridemia (triglycerides of Ͼ 1000 mg/dl) be considered a risk for pancreatitis.